Tango Therapeutics, Inc. (TNGX) compared with its closest peers (KURA, NUVB, IDYA, BDTX, KYMR). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Kura Oncology, Nuvation Bio, Black Diamond Therapeutics, Kymera Therapeutics, Sutro Biopharma, Nuvalent, Xilio Therapeutics, Enanta Pharmaceuticals and Nurix Therapeutics share Tango Therapeutics's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Kura Oncology, Inc. (KURA) | $1.01B | — |
| Nuvation Bio Inc. (NUVB) | $2.13B | — |
| IDEAYA Biosciences, Inc. (IDYA) | $3.63B | — |
| Black Diamond Therapeutics, Inc. (BDTX) | $113.18M | 6.3 |
| Kymera Therapeutics, Inc. (KYMR) | $9.56B | — |
| Sutro Biopharma, Inc. (STRO) | $278.80M | — |
| Nuvalent, Inc. (NUVL) | $9.75B | — |
| Xilio Therapeutics, Inc. (XLO) | $53.17M | — |
| Enanta Pharmaceuticals, Inc. (ENTA) | $377.47M | — |
| Nurix Therapeutics, Inc. (NRIX) | $2.60B | — |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
TNGX overview · TNGX earnings · TNGX financials · TNGX KPIs · TNGX documents · TNGX ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.